NEW YORK (GenomeWeb) – LifeCodexx and Sengenics have partnered to offer LifeCodexx's noninvasive prenatal fetal trisomy PrenaTest in Southeast Asia.
Under the agreement, the PrenaTest will be available to women in Malaysia, Singapore, Thailand, Brunei, Vietnam, the United Arab Emirates, and elsewhere in the Middle East.
"We are very pleased to expand our footprint into Southeast Asia by teaming up with Sengenics with their longstanding expertise in the field of molecular diagnostics services," said LifeCodexx CEO Michael Lutz in a statement, adding that PrenaTest will now be available in almost 50 countries in Europe, the Middle East, and Southeast Asia.
LifeCodexx performs the PrenaTest in its Germany laboratory using next-generation sequencing technology. Going forward, the company plans to switch to an approach that is based on methylation-specific quantitative PCR, for which it recently obtained CE marking.
Sengenics, an immunodiagnostics and therapeutics company, focuses on applications of its Immunome protein array technology, which it acquired from Oxford Gene Technology in 2015.